F&P Of New Zealand Reports 70 Percent Profit Increase From Respirators
This article was originally published in PharmAsia News
New Zealand medical device maker Fisher & Paykel Healthcare says demand for its respiratory humidifier systems and acute care products has been so high the firm expects a 70 percent increase in its net profit this fiscal year. CEO Mike Daniell attributed much of the increase to "substantial orders" by the Group Purchasing Organisation, a hospital group, for U.S. contracts to fill a gap in respirator supplies. The company said it expects a 25 percent revenue growth in the coming year. (Click here for more
You may also be interested in...
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.